Adipose-derived stem cell exosomes as a novel anti-inflammatory agent and the current therapeutic targets for rheumatoid arthritis
TH Chang, CS Wu, SH Chiou, CH Chang, HJ Liao - Biomedicines, 2022 - mdpi.com
Patients with rheumatoid arthritis (RA), a chronic inflammatory joint disorder, may not
respond adequately to current RA treatments. Mesenchymal stem cells (MSCs) elicit several …
respond adequately to current RA treatments. Mesenchymal stem cells (MSCs) elicit several …
New Therapeutic Strategies for the Inflammatory Rheumatoid Arthritis Disease: Emphasizing Mesenchymal Stem Cells and Associated exo-miRNA or exo-lncRNA
The most prevalent inflammatory arthritis and a leading contributor to disability is rheumatoid
arthritis (RA). Although it may not have arrived in Europe until the 17th century, it was …
arthritis (RA). Although it may not have arrived in Europe until the 17th century, it was …
[HTML][HTML] Nitazoxanide reduces inflammation and bone erosion in mice with collagen-induced arthritis via inhibiting the JAK2/STAT3 and NF-κB pathways in fibroblast …
C Li, F Wang, Y Han, J Zhai, Y Jin, R Liu, Y Niu… - Biomedicine & …, 2024 - Elsevier
Highlights•NTZ dose-dependently inhibits the proliferation, migration and invasion of RA-
FLS.•NTZ prevents cell cycle progression and inflammatory cytokines mRNA …
FLS.•NTZ prevents cell cycle progression and inflammatory cytokines mRNA …
[HTML][HTML] The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases
A Świerczek, D Batko, E Wyska - Pharmaceutics, 2024 - mdpi.com
Autoimmune diseases (AIDs) are a group of disorders in which the immune system attacks
the body's own tissues, leading to chronic inflammation and organ damage. These diseases …
the body's own tissues, leading to chronic inflammation and organ damage. These diseases …
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis
R Sen, M Riofrio, JA Singh - Expert Opinion on Drug Safety, 2024 - Taylor & Francis
Introduction Disease-modifying anti-rheumatic drugs (DMARDs) have improved the
outcomes of patients with rheumatoid arthritis (RA). DMARDs are classified into three …
outcomes of patients with rheumatoid arthritis (RA). DMARDs are classified into three …
Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis
Z Ruan, Y Tang, T Gao, C Li, R Guo… - CNS Neuroscience …, 2024 - Wiley Online Library
Background We aimed to compare the efficacy of tocilizumab with conventional
immunotherapy in refractory patients with acetylcholine receptor antibody‐positive (AChR …
immunotherapy in refractory patients with acetylcholine receptor antibody‐positive (AChR …
Safety outcomes of tocilizumab and tofacitinib treatment for rheumatoid arthritis: Target trial emulation
YF Fang, SH Chang, CF Kuo… - International Journal of …, 2024 - Wiley Online Library
Objectives Biological disease‐modifying antirheumatic drugs have been the primary
treatment option for moderate to severe rheumatoid arthritis (RA) in Taiwan since 2010 …
treatment option for moderate to severe rheumatoid arthritis (RA) in Taiwan since 2010 …
Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA
MF Tsoi, L Kearsley-Fleet, N Azadbakht… - …, 2024 - academic.oup.com
Objectives Tocilizumab is an IL-6 receptor humanized monoclonal antibody for the treatment
of rheumatoid arthritis (RA) with intravenous (IV) and subcutaneous (SC) preparations …
of rheumatoid arthritis (RA) with intravenous (IV) and subcutaneous (SC) preparations …
Uticaj Različitih Terapijskih Modaliteta, Citokina I Aktivnosti Bolesti na Bihevioralni Status Bolesnika sa Reumatoidnim Artritisom
S Golubović - 2022 - search.proquest.com
Увод: Реуматоидни артритис (РА) је хронична прогресивна системска болест коју
карактерише симетрични перзистирајући синовитис периферних зглобова. Патолошки …
карактерише симетрични перзистирајући синовитис периферних зглобова. Патолошки …
Tocilizumab for the Treatment of Refractory Morphea: A Systematic Review
D Metko, S Mehta, R Geng, A Mufti… - Journal of Cutaneous …, 2024 - journals.sagepub.com
Tocilizumab for the Treatment of Refractory Morphea: A Systematic Review - Dea Metko,
Shanti Mehta, Ryan Geng, Asfandyar Mufti, Jensen Yeung, 2024 Skip to main content Intended …
Shanti Mehta, Ryan Geng, Asfandyar Mufti, Jensen Yeung, 2024 Skip to main content Intended …